After Zynerba (ZYNE) announced yesterday top line results from the open label Phase 2 clinical trial that assessed the safety and efficacy of Zygel in developmental and epileptic encephalopathies, or DEE, H.C. Wainwright analyst Oren Livnat said the shares have been "punished," which he sees as "unwarranted" since he views the data as encouraging. Investors, comparing Zygel head-to-head with GW Pharma's (GWPH) Epidiolex, appear to be concluding that Zygel looks less efficacious, which he doesn't think is necessarily the case. Furthermore, this line of "reasoning entirely misses the point of this study," which were identifying an efficacy signal and confirming Zygel's likely superior safety profile vs Epidiolex, both of which he thinks Zynerba achieved. Livnat reiterated a Buy rating on Zynerba shares.